linjc16/ctgov huggingface dataset:
Prognostic Value of Sympathetic Modulation in Patients With Heart Failure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether oscillatory pattern of sympathetic nerve activity muscle is an efficient index for the prognosis of patients with heart failure.

Official Title
-----------------
Prognostic Value of Oscillatory Pattern of Sympathetic Nerve Activity Muscle in Patients With Heart Failure

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with systolic heart failure and New York Heart Association (NYHA) Ischemic, hypertensive, or idiopathic etiology Left ventricular ejection fraction less than 40% Exclusion Criteria: Neuromuscular, Orthopedic, Neurologic and Pulmonary Diseases Renal failure Diabetes mellitus type II

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peripheral autonomic control | Evaluate if the reduction in the oscillatory pattern of muscle sympathetic nerve activity is associated with morbidity and mortality in patients with heart failure in a clinical follow-up 12 months | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial baroreflex control |  | 12 months | 
| Blood inflammatory markers |  | 12 months | 
| Cardiac and peripheral autonomic control |  | 12 months | 
| Functional Capacity |  | 12 months |
Measurement of Pulse Pressure Variation and Cardiac Output by a New Application for Android™ (Captesia™)

Study Overview
=================
Brief Summary
-----------------
This study test the agreement and accuracy of Pulse Pressure Variation (PPV) and Cardiac Output (CO) obtained by the Android application Capstesia™ against the gold standard : PPV and CO calculated by thermodilution.

Detailed Description
-----------------
Pulse pressure variation (PPV) remains a good predictor of fluid responsiveness in the OR. However, PPV can be time-consuming to calculate (manual determination), is not always displayed on monitoring screens nor reliable through visual assessment and needs additional devices to be displayed. A new Android application (Captesia) automatically calculates the PPV utilizing a digital photograph of the arterial waveform from the monitor. The application determines the PPV by selecting peaks and troughs of the arterial curve.

Official Title
-----------------
Measurement of Pulse Pressure Variation (PPV) and Cardiac Output (CO) by a New Application for Android™ (Captesia™) : Comparison With PPV and CO Obtained by a Method of Transpulmonary Thermodilution.

Conditions
-----------------
Coronary Bypass

Intervention / Treatment
-----------------
* Other: Calculation of PPV and CO with two methods


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for coronary artery bypass Exclusion Criteria: patients with arrhythmias like atrial fibrillation patients with valvular insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PPV<br>This study will track changes in PPV and CO before and after of volume expansion, which goal is to change the cardiac output. | Other: Calculation of PPV and CO with two methods<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PPV | the Pulse Pressure Variation will be calculated by the Android Application (Captesia) and by the Picco before and after a meneuver of volume expansion, which goal is to change the cardiac output. | at time of surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CO | the Cardiac Output will be calculated by the Android Application (Captesia) and by thermodilution before and after of volume expansion, which goal is to change the cardiac output. | at time of surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pulse pressure variation monitoring, Captesia, cardiac output monitoring
SURPASS Impella 5.5 Study

Study Overview
=================
Brief Summary
-----------------
A multi-center, prospective & retrospective, observational single-arm study of the clinical outcomes up to one year collected from electronic health records of patients which have undergone standard of care implantation of Impella 5.5, regardless of clinical situation or indication. All patients will be enrolled via an IRB-approved Waiver of Informed Consent and HIPAA Authorization. All patients who were supported retrospectively (prior to site IRB approval) with Impella 5.5 at the investigative site will be entered into the SURPASS registry and specified as the retrospective cohort.

Official Title
-----------------
SURPASS Study - The Surgical Unloading Renal Protection And Sustainable Support Study

Conditions
-----------------
Cardiogenic Shock, Acute Decompensated Heart Failure

Intervention / Treatment
-----------------
* Device: Impella 5.5


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Subject has previously undergone an Impella 5.5 implant at a study site Exclusion Criteria: Patients not receiving Impella 5.5

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single arm all comers supported with Impella 5.5<br> | Device: Impella 5.5<br>* Impella 5.5 mechanical circulatory support<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival Outcome | The rate of patients who survived at Impella 5.5 explant, hospital discharge and follow-up up to 1 year | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Impella, Impella 5.5, Bridge to next therapy
Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb

Study Overview
=================
Brief Summary
-----------------
Obtain sputum smears within one day to rule out TB

Official Title
-----------------
Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb

Conditions
-----------------
Pulmonary TB

Intervention / Treatment
-----------------
* Procedure: Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects admitted to Bellevue Hospital for evaluation of possible TB Exclusion Criteria: Unable to produce spontaneous or induced sputum

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TB diagnosis<br> | Procedure: Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.<br>* Sputum induction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Application of Integrated MR-PET in Patients With Gynecologic Cancers

Study Overview
=================
Brief Summary
-----------------
In this prospective cohort study, patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers) and patients with suspicious recurrent gynecologic cancers will be enrolled. The study period is two years and the estimated patient number is about 220. Patients will undergo image study before and after treatment. The diagnostic accuracy of MR-PET in cancer staging and the potential image biomarkers to monitor treatment response and predict treatment outcome will be investigated.

Conditions
-----------------
MR-PET Imaging

Intervention / Treatment
-----------------
* Other: Medical Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers). Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers). Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy. Exclusion Criteria: Age <20 or >90 years old Contraindication for MRI: Contraindication for MR contrast medium (Cre > 2.0) History of other malignancy Prior arthroplasty of hip or pelvic bone surgery with metallic fixation (may cause artifacts on MRI) Pregnant or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cervical cancer<br>Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers). | Other: Medical Imaging<br> <br> |
| endometrial cancer<br>Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers). | Other: Medical Imaging<br> <br> |
| ovarian cancer<br>Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy. | Other: Medical Imaging<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The imaging biomarkers determined by MR-PET |  | 3 months |
The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life

Study Overview
=================
Brief Summary
-----------------
The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life

Official Title
-----------------
The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Other: Preventive Multimedia Teaching Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 20 years of age. The first time to accept the target drug treatment (Iressa, Tarceva) treatment, diagnosis of lung cancer third or fourth stage of the women. There are computer equipment at home to play the disc. can speak, write, read Chinese, clear consciousness, no cognitive impairment. In the medical center of Taipei, a medical department, medical or surgical clinic for treatment. Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: traditional group<br> | |
| Experimental: Multimedia group<br> | Other: Preventive Multimedia Teaching Program<br>* Preventive Multimedia Teaching Program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skindex-29 | Skin-Related Quality of Life | average of 1 month |
Hypernatremia in Hydatid Cyst Treatment

Study Overview
=================
Brief Summary
-----------------
Hypertonic saline (HS) is one of the most widely used scolocidal agents in the treatment of hydatid cysts. Hypernatremia is one of the complications associated with the use of HS. It can cause hypernatremia, acid-base disorder, impaired lung, renal, cardiac and neurological functions and even death. Therefore, caution should be exercised in the use of HS, and open technique should be preferred in surgery.

Official Title
-----------------
Systematic Review of Hypernatremia Following Hydatid Cyst Treatment

Conditions
-----------------
Echinococcosis, Hepatic

Intervention / Treatment
-----------------
* Procedure: Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who developed hypernatremia (plasma sodium value above 145 mmol/L) due to HS use in the treatment of hydatid cyst were included to study - Exclusion Criteria:Patients who developed hypernatremia due to other treatments were excluded from the study. -

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypernatremia<br>Hypernatremia (plasma sodium value above 145 mmol/L) due to HS use in the treatment of hydatid cyst. | Procedure: Treatment<br>* Surgery and PAIR<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevention of hypernatreima | Hypernatremia is plasma sodium value above 145 mmol/L. | 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Echinococcosis, Hepatic, hypernatremia
Volatile Organic Compounds in Staphylococcus Aureus Patients

Study Overview
=================
Brief Summary
-----------------
The zNose® MRSA test is a non-invasive breath test for markers of Staphylococcus aureus, which may predict the probability of bacterial organisms in the anterior nares, throat and respiratory tract, wounds, and anus and therefore be able to replace or supplement current active Methicillin Resistant Staphylococcus Aureus (MRSA) surveillance efforts. It consists of: A collection apparatus for collection of volatile compounds from suspected infection sites onto a sorbent trap or Tedlar bag, as well as for the collection of a separate sample of room air. Analysis of the volatile organic compounds from suspected infection sites and room air by short acoustic wave gas chromatography. Interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of Staphylococcus aureus infection and colonization. This study will test the hypothesis that we can identify the presence of MRSA by sampling the head space above culture media of anterior nare samples provided by patients with MRSA. Additionally, this study will test the hypothesis that we can identify the presence of MRSA by sampling air exhaled through the nostrils (nasal exhalant).

Official Title
-----------------
Detection of Methicillin Resistant Staphylococcus Aureus Colonization Using the zNose®, an Ultra-fast Gas Chromatograph

Conditions
-----------------
Staphylococcus Aureus, Methicillin-resistant Staphylococcus Aureus, Nosocomial Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspicion of staphylococcus aureus infection or colonization Able to give samples for zNose® analysis Exclusion Criteria: Inability to provide sample for zNose® analysis

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Staphylococcus Patients<br>Patients suspected of having Methicillin-resistant and/or methicillin-susceptible staphylococcus aureus. | |
| Control<br>Healthy volunteer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of Methicillin Resistant Staphyloccus aureus | Identification during clinic visit of MRSA | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Staphylococcus aureus, Methicillin-resistant staphylococcus aureus, Nosocomial disease, Electronic nose, Gas chromatography
Laparoscopic Cholecystectomy in Idiopathic Pancreatitis

Study Overview
=================
Brief Summary
-----------------
The causes of acute pancreatitis in Finland are alcohol overuse (60%), cholecystolithiasis (20%) and idiopathic (i.e. etiology unknown)(20%). Acute pancreatitis may recur in over half of cases and may be fatal in severe cases in 30%. Majority of idiopathic pancreatitis are caused by microlithiasis in gall bladder. The purpose of this randomized study is to prevent recurrence of idiopathic pancreatitis by performing laparoscopic cholecystectomy compared to non-operative group in 2 years follow-up of patients.

Detailed Description
-----------------
Etiologic investigations include serum amylase, lipase, triglyceride and calcium determination, as well as abdominal ultrasound scanning. Alcohol consumption is asked by using WHO audit test. After etiology of acute pancreatitis has been confirmed as idiopathic, 100 patients are randomized to laparoscopic cholecystectomy and 100 patients to follow-up of 2 years. Five to seven Finnish university and main central hospitals are participating the study.

Official Title
-----------------
Does Laparoscopic Cholecystectomy Prevent Recurrence in Idiopathic Pancreatitis? A Prospective Multicentre Randomized Study

Conditions
-----------------
Idiopathic Pancreatitis

Intervention / Treatment
-----------------
* Procedure: Laparoscopic cholecystectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: idiopathic pancreatitis Exclusion Criteria: age < 18 years old patients' refusal high operative risks alcohol overuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1:Laparoscopic cholecystectomy<br>Surgery | Procedure: Laparoscopic cholecystectomy<br>* Surgery<br>* Other names: cholecystectomy;|
| No Intervention: 2:controls<br>non-surgical control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence of acute pancreatitis |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| etiology of acute pancreatitis in Finland in 2009-10 |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrence of idiopathic pancreatitis, laparoscopic cholecystectomy, etiology of pancreatitis
Assessment of Normal Values of Esophagogastric Junction (EGJ) Distensibility in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
To assess normal values of EGJ distensibility in healthy volunteers.

Official Title
-----------------
Assessment of Normal Values of Esophagogastric Junction (EGJ) Distensibility in Healthy Volunteers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No history of gastrointestinal disease, especially gastro-esophageal reflux disease BMI = 18-30 kg/m² Caucasian race Subject signed the informed consent form and is able to adhere to study protocol Exclusion Criteria: Age < 18 years Previous esophageal or gastric surgery Co-morbidities (including cardiopulmonary disease, collagen diseases, obesity, coagulation disorders and co-morbidity hindering upper gastrointestinal endoscopy) Patients using anticoagulants Patients unable to give informed consent Smoking History of alcohol abuse or current excessive alcohol consumption (> 2 alcoholic beverages per day or > 14 alcoholic beverages per week)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy volunteers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| normal values of esophagogastric junction (EGJ) distensibility (mm2/mmHg) in healthy volunteers as measured with the EndoFLIP device | EGJ distensibility as measured by the index of the narrowest cross sectional area (mm2) and the corresponding intrabag pressure (mmHg) | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establishing a cut-off value of EGJ distensibility (mm2/mmHg) based on the 90% percentile distribution of measurements performed in healthy volunteers. |  | 3 months |